Skip to main content

Table 1 Serum-VEGF, serum-bFGF and urinary-bFGF levels at diagnosis, according to patient and tumour characteristics

From: Prognostic impact of blood and urinary angiogenic factor levels at diagnosis and during treatment in patients with osteosarcoma: a prospective study

 

Serum VEGF (pg/mL)

Serum bFGF (pg/mL)

Urinary bFGF (ng/g creatinine)

N

Median [Q1-Q3]a

P value b

N

Median [Q1-Q3]a

P value b

N

Median [Q1-Q3]a

P value b

All

246

428 [274–685]

 

242

4.3 [3–13]

 

129

5.2 [2.7–10.4]

 

Gender

  

0.94

  

0.10

  

0.30

 Male

136

432 [286–675]

 

133

5 [3–14]

 

70

4.5 [2.4–9.6]

 

 Female

110

427 [252–686]

 

109

4 [3–11]

 

59

5.6 [3.1–10.9]

 

Age

  

0.65

  

0.07

  

0.03

  < 13 years

71

466 [223–692]

 

71

7 [3–18]

 

36

7.5 [4.8–12.9]

 

 13–18 years

106

399 [271–686]

 

104

4 [3–13]

 

59

4.1 [2.2–8.9]

 

  > 18 years

69

440 [327–642]

 

67

3 [3–10]

 

34

5.3 [1.9–11.4]

 

Tumour size

  

0.003

  

0.24

  

0.28

  < 10 cm

110

391 [222–567]

 

108

5 [3–12]

 

59

4.9 [2.1–9.6]

 

  ≥ 10 cm

121

504 [308–738]

 

119

3 [3–13]

 

62

5.3 [2.9–11.6]

 

Initial stage c

  

0.64

  

0.16

  

0.17

 Localized

164

431 [258–689]

 

162

4 [3–11]

 

92

5176 [2.4–9.2]

 

 Doubtful lesions

40

418 [335–711]

 

39

7 [3–15]

 

21

4.9 [3.3–12.2]

 

 Metastases

39

396 [274–621]

 

38

3 [3–7]

 

15

9.6 [3.5–17.1]

 

Histologic subtype

  

0.36

  

0.57

  

0.46

 Osteoblastic

154

435 [303–735]

 

152

5 [3–13]

 

82

5.3 [2.8–10.8]

 

 Fibroblastic

10

399 [205–512]

 

11

7 [3–13]

 

2

2.6 [1.8–3.3]

 

 Chondroblastic

40

461 [280–610]

 

38

4 [3–11]

 

26

5.5 [3.5–11.4]

 

 Telangiectasic

7

283 [178–692]

 

7

3 [3–3]

 

4

5.3 [4–77.3]

 

 Other

25

365 [241–484]

 

24

4 [3–14]

 

13

3.1 [1.8–7.9]

 

Alkaline phosphatase

  

0.11

  

0.21

  

0.33

  < 1.25 x ULN

137

404 [252–644]

 

135

5 [3–11]

 

74

4.9 [2.5–9.6]

 

  ≥ 1.25 x ULN

70

472 [305–736]

 

69

3 [3–13]

 

40

6.1 [3–13.6]

 

Histological response d

  

0.92

  

0.40

  

0.44

 Good

138

435 [283–732]

 

137

5 [3–13]

 

85

5.1 [2.9–10.2]

 

 Poor

76

429 [314–647]

 

74

4 [3–11]

 

31

4.1 [2.1–8.9]

 
  1. a[Q1-Q3]: inter-quartile range
  2. bKruskal-Wallis test comparing the distributions between the different subsets
  3. cLung metastases on CT were defined by ≥1 nodule >10 mm, and/or ≥2 nodules from 5 to 9 mm, and/or ≥5 well limited nodules <5 mm. Other types of lesion were considered as doubtful lesions
  4. dResults by quartile of the distributions are available in Additional file 5 Table-S3
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us